Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
Bengt Eriksson
REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when
